AOA Dx is transforming the future of women’s health with AKRIVIS GD™, a first of its kind liquid biopsy test that analyzes tumor marker gangliosides to accurately detect early-stage ovarian cancer.
* 75% versus the 25% of ovarian cancer cases which are presently detected at stage I or II
Ovarian cancer is the fifth leading cause of cancer deaths in women. 94% of women start to experience symptoms in Stage I, while only 20% of all cases are diagnosed in Stage I or II.
Cancers diagnosed beyond stage I or II have a 28% survival rate with a 94% recurrence. By 2035 new cases will increase by 55% and deaths will increase by 67%. Women deserve better.
Ovarian cancer is the second most expensive cancer to treat, second only to brain. The average cost of care for women with ovarian cancer in the first year after surgery is approximately $100,000.
Early diagnosis of ovarian cancer can halve the number of deaths and significantly reduce the costs of treatment and recurrence. Today, there is no diagnostic test for ovarian cancer and current methods lack sensitivity and specificity in stages I and II. In the US, the average time to diagnosis is 9 months, while early-stage tumors double in volume every 4 months. By the time a diagnosis of ovarian cancer is considered, the cancer has usually spread beyond the ovaries.
As the first diagnostic test developed on AOA Dx’s groundbreaking GlycoLocate™ platform, AKRIVIS GD™ leverages tumor marker ganglioside technology to provide a liquid biopsy test to accurately detect ovarian cancer.
Preliminary clinical studies demonstrate high sensitivity and specificity across all cancer stages in both premenopausal and postmenopausal women. Early data is being cross validated in a large multi-center prospective clinical trial. AKRIVIS GD™ is addressing the urgent and unmet need for better early-stage ovarian cancer detection.
Change the landscape of ovarian cancer for good with AKRIVIS GD™ and help more women get life-saving treatment, sooner
Ovarian Cancer Coalition (ovarian.org)
https://cancerstatisticscenter.cancer.org/?_ga=2.169703393.1738472685.1671898438-1126230544.1671808281#!/cancer-site/Ovary
https://jamanetwork.com/journals/jama/fullarticle/198893
Gorski JW, Quattrone M, van Nagell JR, Pavlik EJ. Assessing the Costs of Screening for Ovarian Cancer in the United States: An Evolving Analysis. Diagnostics. 2020; 10(2):67. https://doi.org/10.3390/diagnostics10020067